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non-pharmacological cost avoidance assessment we determined that apixaban can 
be a cost saving alternative in the long term. Versus SoC (warfarin), apixaban may 
be the only NOAC with consistent benefit on all relevant events. Consistent with 
trial data, lifetime modeling suggested reduction in the mortality.
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lAtin AmeriCA Countries
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Objectives: AF is the most common chronic cardiac arrhythmia worldwide and is 
an important risk factor for morbidity related mainly to an increased risk of cerebro-
vascular events and heart failure. This study examined the prevalence of comor-
bidities among patients receiving treatment for AF in 4 Latin America countries to 
convey a more comprehensive picture of the total disease burden. MethOds: For 
study purposes, co-morbidity was defined as the presence of one or more disorders 
in addition to a primary disease, or the effect of such additional disorders. A 3-step 
process was conducted in order to understand treatment patterns for patients suffer-
ing from AF: 1) health care assessment per country; 2) evaluate patient’s information; 
and 3) data analysis to understand and determine treatment algorithms. Data were 
collected through 59 face-to-face interviews with cardiologists in Argentina, Brazil, 
Chile, and Venezuela. Results: Analysis per country suggested that, in Chile and 
Venezuela, 98% and 94% of patients, respectively, reported at least one co-morbidity. 
In Argentina this pattern was observed in 81% of the patients, whereas in Brazil 
this was 78%. Findings revealed that the main 5 comorbidities associated with AF 
were: 1) Hypertension: LatAm 43%, Argentina 28%, Brazil 45%, Chile 43%, Venezuela 
33%; 2) Dyslipidemia: LatAm 22%, Argentina 11%, Brazil 25%, Chile 21%, Venezuela 
18%; 3) Diabetes: LatAm 13%, Argentina 8%, Brazil 11%, Chile 10%, Venezuela 18%; 
4) Cardiopathies: LatAm 8%, Argentina 4%, Brazil 8%, Chile 8%, Venezuela 9%; 
and 5) Thyroid disease: LatAm 7%, Argentina 4%, Brazil 3%, Chile 12%, Venezuela 
9%. cOnclusiOns: Overall, the analysis suggests that hypertension is the main 
co-morbidity associated with AF, followed by dyslipidemia and diabetes. The health 
burden carried by patients often extends far beyond AF. Physicians should carefully 
consider comorbidities and concomitant medications when managing patients.
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iCeberg Phenomenon oF heArt FAilure in hosPitAlized PAtients:  
A multiCentriC Cross seCtionAl study
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Objectives: Heart failure (HF) ranks high in hospital utilization, cost and quality/
safety consequences. We studied occult HF as secondary diagnosis (2Dx) in a multi-
centric study of the A-HCUPs. MethOds: A multi-centric cross sectional study of 1 
year hospital discharges adapted HCUPs for Argentina. We estimated HF by HCUPs’ 
CCS#108 SL (heart failure) in 2Dx to measure submerged HF; obtained HF in first diag-
nosis (1Dx), and 365 day readmissions (ReH), < 30 day ReH, mortality and case fatality. 
2Dx1= in first secondary Dx; 2Dx5= fifth 2Dx, etc. International dollars PPP, (UN Data: 
1Arg$ = 1.608 PPP, 2008) were used. Results: Among 45466 discharges ≥ 19 years 
old, we found 1178 discharges with CCS#108 among 1Dx (incidence: 2,59%*; 95%CI 
2,44-2,74%); mortality 0,24% ** (95%CI 0,20-0,29%); 365 days ReH was 60,9% (95%CI 58,1- 
63,7%) and < 30 day ReH of 18,1% (95%CI 15,9- 20,3%). 864 discharges had CCS #108 (HF) 
among any 2Dx (from 1 to 10 2Dx), (incidence: 1,90%; 95%CI 1,77-2,03%) (p< 0,001 vs*), 
descending from 2Dx1: 316, 2Dx5: 89; and 2Dx8: 36 discharges. HF was one among 
several multi-morbid conditions. Outcomes of discharges with 2Dx1 are 365 day ReH: 
57,3 % (95%CI 51,8-62,7%) and < 30 day ReH: 17,1% (95%CI 12,9- 21,2%), mortality 0,09 
(95%CI 0,06-0,12%,(p< 0,001 vs**), case fatality: 12,66% (95%CI 8,99- 16,32%). Mean cost 
per discharge was 7 907 I$ PPP and median cost 1 917 I$PPP for HF in 1Dx; while mean 
was 23316 I$PPP and median cost 12796 I$PPP for CCS #108 in 2Dx5. cOnclusiOns: 
HF is the leading CCS among several criteria of ranking of discharges. Is one of the 
leading causes of admissions as detected by 1Dx. However, HF is frequently sub-
merged as a 2Dx, causes significant mortality, costs and readmissions (ReH). Quality, 
safety and economic studies should consider HF as secondary diagnosis.
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Objectives: Transvenous lead extraction is increasingly required. The aim of this 
study was to determine which factors influence the difficulty of a lead extraction 
procedure through the analysis of a high-volume centre database. MethOds: A 
total of 889 permanent leads were extracted from 469 patients. Factors influencing 
the difficulty of a procedure were assessed using a multivariate logistic regres-
sion model. The fluoroscopy time of the procedure was taken as index of diffi-
culty. Results: From January 2003 to December 2012 , 932 of 946 (98.5%) leads were 
completely removed. Major complications occurred in 1.3% patients. No deaths 
occurred. Median fluoro time was 8.4 min (3.2 - 17.1). A procedure was classified as 
difficult when fluoro time was greater then 31.2 min (90th percentile). At a multivari-
ate analysis the predictors of a difficult procedure were the number of extracted 
leads (OR 1.71, 95%CI 1.06 – 2.8), the presence of screw leads (OR 5.68; 95%CI 1.9 
– 16.9), the presence of dual coil shock leads (OR 5.01, 95%CI 1.27 – 19.8), the years 
since the oldest lead was implanted (OR 1.23, 95%CI 1.15 – 1.31), the absence of leads 
with vegetation (OR 6.76, 95%CI 1.35 – 33.3). The female gender, the patient age at 
extraction, the presence of tachy leads, the presence of lead failure weren’t predic-
ObjectivOs: Identificar el impacto de la obligatoriedad de presentar una 
Evaluación Económica (EE) para la inclusión de medicamentos en el Cuadro Básico 
Nacional en las publicaciones de EE relacionada con el área de reumatología en 
México. MetOdOlOgíAs: Se realizó una búsqueda sistemática de las publi-
caciones de EE y reumatología publicados entre 1995 y 2011. Los estudios de EE 
fueron clasificados por tres expertos en economía de la salud con base a los criterios 
de Drummond, Sí los estudios contemplan comparación de dos o más alterna-
tivas y sí valoran los costos y consecuencias de las alternativas examinadas se 
dice que es un estudio de evaluación económica completa (EEC). Se valoró sí la 
modificación en el año 2003 tuvo impacto significativo en términos de número 
de publicaciones. ResultAdOs: Se identificaron un total de 263 artículos de EE 
entre 1995 y 2011, 93(35%) de fueron EEC. En el periodo 1995-2002 se identificaron 
56 estudios, 19(34%) EEC. En el periodo de 2003-2011 (después de la modificación 
del reglamento) se identificaron un total de 207 publicaciones de EE, 74(36%) EEC. El 
79% de las publicaciones se concentra en el periodo 2003-2011, con un total de 207 
publicaciones. Del total de publicaciones las relacionadas con reumatología fueron 
3% (n= 9) de las cuales 33% fueron completas, 67% fueron parciales. Se destaca que 
antes de la modificación del reglamento en 2003 se detectó un estudio de EE/reuma-
tología mientras que después del año 2003 el número de publicaciones ascendió a 8 
artículos. cOnclusiOnes: La EE en México a través del número de publicaciones se 
ha ido desarrollando notablemente, asimismo el hacer obligatorio el presentar un 
estudio de EE para la inclusión de un insumo al Cuadro Básico y Catálogo de Insumos 
del Sector Salud fue un punto de partida para el desarrollo de la EE en México.
reseArCh on methods – Conceptual Papers
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A uniFied methodologiCAl FrAmework For the eConomiC eVAluAtion 
oF therAPeutiC mediCAl deViCes
Iglesias C.P.
University of York, York, UK
To inform policy decisions economic evaluation (EE) studies require the system-
atic identification and (quantitative) synthesis of the relevant evidence base on 
the clinical effectiveness, quality of life (QoL) and costs associated with the use of 
competing health technologies. Existing methods for EE are linked to principles of 
evidence-based medicine and, as such, are geared primarily towards the evaluation 
of pharmaceuticals. Some authors have claimed that medical devices (MDs) cannot 
be evaluated using the same principles. We take the opposite viewpoint and argue 
that used within the right evaluative framework existing EE methods are indeed 
appropriate to assess the cost effectiveness of therapeutic MDs. What makes the 
(economic) evaluation of MDs challenging is the fact that the quantity, quality, and 
characteristics of the evidence base around them, is often fragmented, heteroge-
neous and associated with high levels of uncertainty. In these circumstances it is 
important to acknowledge the value of eliciting and quantitatively summarising 
physicians and other experts’ beliefs regarding the effectiveness and resource use 
demands associated with MDs already in use. Using real life examples this paper 
shows how a Bayesian stepwise iterative approach has helped address some of the 
challenges associated with the EE of MDs, while guiding policy decisions regard-
ing technology adoption, research funding and design. Relevant steps include: a) 
identification of existing evidence base and elicitation of experts’ beliefs on clinical 
effectiveness , QoL and costs - i.e. “a priori evidence base”; b) quantitative synthesis 
of this a priori evidence base to inform the parameters of an EE model; (c) initial 
estimation of the model; d) assessment of the economic value of conducting fur-
ther research (VoI); e) collection of new patient level data (PLD) in a pilot study; 
(f) new evaluation of the EE model updating the prior estimates using primary PLD; 
g) further VoI analysis.
diseAse-sPeCiFiC studies
CArdioVAsCulAr disorders – Clinical outcomes studies
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Objectives: To determine the clinical consequences and it’s associated costs of the 
usage of oral anticoagulation therapy for the treatment of atrial fibrillation (AF) in 
Colombia by establishing the cost per disease related event. MethOds: We used a 
6-week cycle length, 17 functional state Markov model of the main clinical outcomes 
in the lifetime of a hypothetical cohort of 1,000 patient with AF per treatment arm. 
The pivotal clinical studies for apixaban, dabigatran, rivaroxaban compared to war-
farin were the source of safety and efficacy data. Data for the analysis was extracted 
from this literature using indirect comparison methods. Costs in Colombian pesos 
2012 are expressed in American dollars (1 US$ = COP$ 1785). To estimate costs, we 
analyzed resource use of a sample of 53 stroke, 148 myocardial infarction, 6 systemic 
embolism patients in San Ignacio University Hospital. Results were validated by an 
expert panel. Results: The number of events associated with each anticoagulant 
therapy (apixaban, dabigatran 110mg, dabigatran 150mg, rivaroxaban and warfarin, 
respectively) were: stroke and systemic embolism 349, 363, 351, 360, 369. ISTH major 
bleedings 235, 212, 233, 280, 277; clinically relevant non major bleedings 342, 337, 357, 
395, 383; myocardial infarctions 102, 114, 116, 101, 104; and event related deaths 459, 
485, 475, 469, 481. Apixaban could be associated with savings in non pharmacological 
cost of $ 360, $170, $145 and $311 per treated patient compared to dabigatran 110mg, 
dabigatran 150mg , rivaroxaban and warfarin, respectively. cOnclusiOns: In this 
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sion was used to estimate the odds ratio of the outcome events for patients whose 
treatment in the week before event date included statins and BBs as compared to 
patients whose treatment included statins and other BPLD(s). Results: Patients on 
statins and BBs showed substantially higher risks for cardiovascular death (OR= 2.12, 
95%CI: 1.81–2.49), all-cause death (OR= 1.64, 95%CI: 1.49–1.81), CVD events (OR= 1.96, 
95%CI: 1.80–2.12) and hospitalization for CVD (OR= 1.99, 95%CI: 1.82–2.17) as com-
pared to patients on statins and other BPLDs. Sensitivity analyses suggest that this 
higher risk is not due to differences in prescription patterns based on perceived 
disease severity (indication bias). cOnclusiOns: In elderly hypertensive patients, 
the concurrent use of statins and BBs is associated with less effective primary 
prevention in comparison to the use of statins in combination with other BPLDs. 
Consequently, the difference observed in the efficacy of different classes of BPLDs 
in elderly populations in primary prevention remains significant in the subpopula-
tion receiving statins. Further studies should be conducted to confirm this finding.
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Objectives: We examined the potential clinical implications of prescribing pat-
terns of generic statins within 11 Latin American markets (LA11). In LA11, generic 
versions of pravastatin, simvastatin and atorvastatin are available, however, each 
statin has a different LDL-cholesterol (LDL-C) lowering efficacy that may ulti-
mately result in differences in the incidence of CV events. 2011 LA11 prescription 
data indicate that statins are prescribed at doses that do not yield equivalent 
LDL-C lowering. Thus we calculated the weighted average daily doses (WADDs) 
of pravastatin, simvastatin and atorvastatin within LA11 and estimated the aver-
age LDL lowering with each statin, and the incidence of CV events. MethOds: 
The WADDs of prescribed simvastatin, pravastatin and atorvastatin in LA11 were 
derived from IMS data. The LDL-C modifying potencies of the WADDs were inter-
polated from dose response curves from Nicholls et al (Am J Cardiol, 2010), and 
Law et al (BMJ, 2003). The relationship between LDL-C reduction and the result-
ant impact on cardiovascular events was derived from the Cholesterol Treatment 
Trialists’ Collaboration (CTTC, Lancet 2010), where a 1mmol/L reduction in 
LDL-C, translated to a 22% reduction in major cardiovascular events. Results: 
Across LA11, the WADDs for pravastatin, simvastatin and atorvastatin were 
24.9mg, 22.4mg and 20.6mg, respectively. The corresponding reductions in LDL-C 
at these doses were estimated to be 25.0%, 33.4% and 40.6%. Assuming a pre-
treatment LDL-C of 4.0mmol/L, these lipid changes would lead to reductions 
in the risk of a major coronary/stroke event of 22.0%, 29.4% and 35.8%, respec-
tively. cOnclusiOns: At currently prescribed WADDs in LA11, the real world 
use of atorvastatin provides a superior reduction in LDL-C to either simvastatin 
or pravastatin, and hence would be expected to result in a greater reduction in 
cardiovascular events.
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Objectives: Diuretics are drugs of first choice in the treatment of hypertension. 
The aim of this study was to analyze the consumption of diuretics in Serbia in the 
period from 2006 to 2010 year. MethOds: The data about the use of drugs were 
taken from the Agency for Drugs and Medical Devices of the Serbia. Results: The 
use of diuretics during the observed period in Serbia is quite small and it ranged 
from 5 to 6% of the total consumption of all drugs from the C group. Furosemide 
was the most frequently used diuretic. In the five year period furosemide con-
sumption ranged from 33-55% of the total consumption of all diuretics. The second 
largest consupmtion during first four years of the study was that of indapamide. 
Indapamide consumption in the fifth year was at the fourth position. At the third 
position in drug consumption in the first four years was hydrochlorothiazide. Use 
of hydrochlorothiazide in 2010 took second place. Spironolactone has occupied 
the fourth position in the first four years. During the last years of the period 
spironolactone occupied the third position. Consumption of all other diuretics 
was small and it was only a few percent of the total consumption of all diuret-
ics. cOnclusiOns: In Serbia, in the observed period, consumption of diuterics 
is two to three times lower in comparison with the consumption of diuretics 
in Norway and Finland. This research was supported by Provincial Secretariat 
for Science and Technological Development, Autonomous Province of Vojvodina 
project No 114-451-2458/2011 and by Ministry of Science, Republic of Serbia, pro-
ject no 41012.
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Objectives: Drugs of first choice in the treatment of hypertension are: β -blockers, 
tiazide diuretics, ACE inhibitors, angiotensin receptor inhibitors and Ca chan-
nel blockers. The aim of this study was to analyze the consumption of antihy-
pertensive drugs in Serbia in the period from 2007 to 2011 year. MethOds: The 
data about the use of drugs were taken from the Agency for Drugs and Medical 
Devices of the Serbia. Results: The use of diuretics during the observed period 
in Serbia is quite small and it ranged from 5 to 6% of the total consumption of all 
drugs from the C group. Consumption of β -blockers was around 12% during all 5 
years. Consumption of calcium channel blockers was less than 12% of the total 
consumption of all drugs from group C in the first 2 years of the observed period. 
However, consumption of such drugs in the last 3 years growing over 18% of the 
tors of a difficult procedure. cOnclusiOns: Factors influencing the difficulty of 
an extraction procedure are the number of leads, the presence of screw leads, the 
presence of dual-coil tachy leads, the years since the oldest lead was implanted and 
the absence of leads with vegetation.
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lA utilidAd PrediCtiVA del eurosCore Puede ser mejorAdA Al 
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ObjectivOs: El Euroscore(EU) es el modelo predictivo más usado en cirugía cardi-
aca; sin embargo, sobreestima el riesgo y la información necesaria para calcularlo 
no siempre está disponible. Este estudio fue diseñado para: 1). Definir si adicio-
nar el valor preoperatorio de hemoglobina (HB), péptido natriurético tipo B(BNP) o 
ambos, al EU, mejoran su capacidad predictiva sobre morbimortalidad a 6 meses 
de seguimiento postoperatorio en toda la muestra y en los pacientes diabéticos; y 
2). Evaluar la utilidad de EU en nuestro medio. MetOdOlOgíAs: Se incluyeron 492 
pacientes quirúrgicos cardiacos. Se comparò directamente la capacidad predictiva 
de BNP y/o HB vs EU. Luego se evaluó en que tanto la incorporación de BNP y/o HB 
al EU, adicionaron en términos de lograr mejor discriminación. Para cada uno de 
los desenlaces se construyeron y compararon curvas ROC. ResultAdOs: Sobre 
mortalidad, BNP o HB no adicionan capacidad predictiva al EU ni en la muestra 
global ni en diabéticos. La mortalidad intrahospitalaria fue mejor discriminada 
por EU aislado: área bajo la curva ROC (ABC-ROC): 0.83(IC95%0.75-0.92) y a 6 meses, 
ABC-ROC 0.73 (IC95% 0.64-0.83); en pacientes diabéticos, ABC-ROC 0.95 (IC95%0.91-
1.00) para mortalidad intrahospitalaria y a 6 meses, ABC-ROC 0.84 (IC95% 0.74-0.98). 
La discriminación obtenida con BNP fue buena para bajo gasto cardiaco: ABC-ROC, 
0.72 (IC95% 0.67-0.77); e insuficiencia renal aguda ABC-ROC 0.75 (IC95% 0.76-0.84). 
Los mejores predictores de transfusión fueron EU+HB ó BNP+HB. EU mostró buena 
capacidad predictiva (ABC-ROC≥ 0.70) sobre morbilidad combinada, estancia pro-
longada en cuidado intensivo, bajo gasto cardiaco e insuficiencia renal y a 6 meses 
en la discriminación de evento cerebrovascular, tanto en el grupo total como en 
diabéticos. cOnclusiOnes: La capacidad discriminatoria de EU para mortalidad 
en nuestro medio es muy buena, especialmente en diabéticos. BNP o HB no adi-
cionan capacidad predictiva. En la mayor parte de los desenlaces de morbilidad la 
discriminación obtenida con BNP aislado es comparable a EU.
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Objectives: To compare changes in blood pressure after 8 weeks of therapy 
between a fixed-dose combination (FDC) of amlodipine/losartan and amlodipine/
valsartan using a network meta-analysis because there are no trials directly compar-
ing amlodipine/losartan to amlodipine/valsartan. MethOds: A systematic search 
identified six randomized controlled trials of study FDCs and their component 
monotherapies; 3 included amlodipine/losartan and 3 included amlodipine/vals-
artan. Conventional fixed-effects methods were used to conduct the comparisons. 
The change in sitting diastolic and systolic blood pressure (sitDBP, sitSBP) at 8 weeks 
post-randomization was the primary and secondary effect measures. Results: 
Amlodipine/losartan 5/50 mg produced greater reductions in sitDBP (-1.27 mmHg, 
95% confidence interval (CI) -5.7 - 2.2) and sitSBP (-3.7 mmHg, 95% CI -9.0 - 2.9) than 
amlodipine/valsartan 5/80 mg. Amlodipine/losartan 5/100 mg produced a greater 
reduction in sitDBP (-0.45 mmHg, 95% CI -3.7 - 2.7) than amlodipine/valsartan 5/160 
mg while amlodipine/valsartan 5/160 mg had a greater reduction in sitSBP (0.2 
mmHg, 95% CI -6.2 - 6.0) than amlodipine/losartan 5/100 mg. The confidence of supe-
rior antihypertensive efficacy for COZAAR XQ 5/50 mg than amlodipine/valsartan 
5/80 mg is 77% for sitDBP and 89% for sitSBP, while the confidence of greater efficacy 
for amlodipine/losartan 5/100 mg than amlodipine/valsartan 5/160 mg is 61% for 
sitDBP and 48% for sitSBP. With 95% CI, the reduction difference in sitDBP and sitSBP 
between amlodipine/valsartan 5/80 mg and amlodipine/losartan 5/100 mg is not 
expected to exceed 1.6 mmHg and 1.26 mmHg, respectively, and not expected to 
exceed 2.31 mmHg and 5.38 mmHg, respectively with amlodipine/valsartan 5/160 
mg versus amlodipine/losartan 5/100 mg. cOnclusiOns: The blood pressure low-
ering effect with amlodipine/losartan and amlodipine/valsartan was comparable. 
The findings from this network metaanalysis do not indicate a potential superiority 
of the reductions realized with amlodipine/valsarta relative to amlodipine/losartan.
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Objectives: Differences in efficacy of different classes of blood pressure lowering 
drugs (BPLDs) have been observed in elderly primary prevention populations, with 
beta-blockers (BBs) reported to be less efficacious for primary prevention. In this 
study, we assessed if these differences remained significant in patients that use 
statins concurrently. MethOds: We conducted a series of population-based nested 
case-control studies using administrative data from 104,023 diagnosed hypertensive 
patients without recent antecedents of diabetes or cardiovascular disease (CVD) in 
the province of Quebec (Canada) between 2000 and 2004. Follow-up ended either 
with an outcome event, or at the end of 2009. Individuals with an outcome event (all-
cause death, CVD event) were considered cases. Controls were matched according 
to age, sex, date of cohort entry, and comorbidity index. Conditional logistic regres-
